Avanos Medical Analyst Ratings
Avanos Medical Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 02/22/2023 | -3.45% | Morgan Stanley | $26 → $28 | Maintains | Underweight |
| 01/06/2023 | -10.34% | Morgan Stanley | $24 → $26 | Maintains | Underweight |
| 11/03/2022 | 17.24% | Keybanc | $38 → $34 | Maintains | Overweight |
| 10/11/2022 | -17.24% | Morgan Stanley | $28 → $24 | Maintains | Underweight |
| 08/10/2022 | 31.03% | Keybanc | $41 → $38 | Maintains | Overweight |
| 07/18/2022 | -3.45% | Stifel | $37 → $28 | Maintains | Hold |
| 07/15/2022 | -3.45% | Morgan Stanley | $33 → $28 | Maintains | Underweight |
| 05/05/2022 | 13.79% | Morgan Stanley | $36 → $33 | Maintains | Underweight |
| 02/24/2022 | 41.38% | Keybanc | $47 → $41 | Maintains | Overweight |
| 01/07/2022 | 24.14% | Morgan Stanley | $37 → $36 | Maintains | Underweight |
| 08/04/2021 | 41.38% | Morgan Stanley | $45 → $41 | Maintains | Underweight |
| 08/04/2021 | 55.17% | Stephens & Co. | $60 → $45 | Downgrades | Overweight → Equal-Weight |
| 08/04/2021 | 62.07% | Keybanc | $55 → $47 | Maintains | Overweight |
| 01/08/2021 | 89.66% | Keybanc | $47 → $55 | Maintains | Overweight |
| 12/15/2020 | 55.17% | Morgan Stanley | $36 → $45 | Maintains | Underweight |
| 11/04/2020 | 24.14% | Morgan Stanley | $31 → $36 | Maintains | Underweight |
| 11/04/2020 | 62.07% | Keybanc | $43 → $47 | Maintains | Overweight |
| 08/05/2020 | 48.28% | Keybanc | $45 → $43 | Maintains | Overweight |
| 05/07/2020 | 6.9% | Morgan Stanley | $29 → $31 | Maintains | Underweight |
| 04/27/2020 | 55.17% | Keybanc | $48 → $45 | Maintains | Overweight |
| 04/13/2020 | — | Barclays | Upgrades | Underweight → Equal-Weight | |
| 04/01/2020 | 10.34% | Stifel | $35 → $32 | Maintains | Hold |
| 03/27/2020 | 0% | Morgan Stanley | $32 → $29 | Maintains | Underweight |
| 03/23/2020 | 3.45% | Stephens & Co. | $40 → $30 | Maintains | Overweight |
| 12/17/2019 | 10.34% | Morgan Stanley | $36 → $32 | Maintains | Underweight |
| 11/07/2019 | 20.69% | Stifel | $45 → $35 | Downgrades | Buy → Hold |
| 11/06/2019 | — | Raymond James | Downgrades | Outperform → Market Perform | |
| 11/06/2019 | 65.52% | Keybanc | $51 → $48 | Maintains | Overweight |
| 08/07/2019 | 65.52% | Raymond James | $57 → $48 | Maintains | Outperform |
| 02/27/2019 | 124.14% | Keybanc | $67 → $65 | Maintains | Overweight |
| 01/04/2019 | 24.14% | Barclays | $59 → $36 | Downgrades | Equal-Weight → Underweight |
| 12/18/2018 | 131.03% | Keybanc | $68 → $67 | Maintains | Overweight |
| 10/16/2018 | 137.93% | Barclays | → $69 | Initiates Coverage On | → Equal-Weight |
| 10/11/2018 | 113.79% | Morgan Stanley | $60 → $62 | Maintains | Underweight |
| 08/21/2018 | — | Raymond James | Upgrades | Market Perform → Outperform | |
| 08/08/2018 | 106.9% | Morgan Stanley | $58 → $60 | Maintains | Underweight |
| 08/08/2018 | 158.62% | Keybanc | $66 → $75 | Maintains | Overweight |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 02/22/2023 | -3.45% | 摩根士丹利 | $26 → $28 | 維護 | 體重不足 |
| 01/06/2023 | -10.34% | 摩根士丹利 | $24 → $26 | 維護 | 體重不足 |
| 11/03/2022 | 17.24% | KeyBanc | $38 → $34 | 維護 | 超重 |
| 10/11/2022 | -17.24% | 摩根士丹利 | $28 → $24 | 維護 | 體重不足 |
| 08/10/2022 | 31.03% | KeyBanc | $41 → $38 | 維護 | 超重 |
| 07/18/2022 | -3.45% | Stifel | $37 → $28 | 維護 | 保持 |
| 07/15/2022 | -3.45% | 摩根士丹利 | $33 → $28 | 維護 | 體重不足 |
| 05/05/2022 | 13.79% | 摩根士丹利 | $36 → $33 | 維護 | 體重不足 |
| 02/24/2022 | 41.38% | KeyBanc | $47 → $41 | 維護 | 超重 |
| 01/07/2022 | 24.14% | 摩根士丹利 | $37 → $36 | 維護 | 體重不足 |
| 08/04/2021 | 41.38% | 摩根士丹利 | $45 → $41 | 維護 | 體重不足 |
| 08/04/2021 | 55.17% | 斯蒂芬斯公司 | $60 → $45 | 評級下調 | 超重→等重 |
| 08/04/2021 | 62.07% | KeyBanc | $55 → $47 | 維護 | 超重 |
| 01/08/2021 | 89.66% | KeyBanc | $47 → $55 | 維護 | 超重 |
| 12/15/2020 | 55.17% | 摩根士丹利 | $36 → $45 | 維護 | 體重不足 |
| 11/04/2020 | 24.14% | 摩根士丹利 | $31 → $36 | 維護 | 體重不足 |
| 11/04/2020 | 62.07% | KeyBanc | $43 → $47 | 維護 | 超重 |
| 08/05/2020 | 48.28% | KeyBanc | $45 → $43 | 維護 | 超重 |
| 05/07/2020 | 6.9% | 摩根士丹利 | $29 → $31 | 維護 | 體重不足 |
| 04/27/2020 | 55.17% | KeyBanc | $48 → $45 | 維護 | 超重 |
| 04/13/2020 | — | 巴克萊 | 升級 | 重量不足的→等重 | |
| 04/01/2020 | 10.34% | Stifel | $35 → $32 | 維護 | 保持 |
| 03/27/2020 | 0% | 摩根士丹利 | $32 → $29 | 維護 | 體重不足 |
| 03/23/2020 | 3.45% | 斯蒂芬斯公司 | $40 → $30 | 維護 | 超重 |
| 12/17/2019 | 10.34% | 摩根士丹利 | $36 → $32 | 維護 | 體重不足 |
| 11/07/2019 | 20.69% | Stifel | $45 → $35 | 評級下調 | 購買→Hold |
| 11/06/2019 | — | 雷蒙德·詹姆斯 | 評級下調 | 跑贏→市場表現 | |
| 11/06/2019 | 65.52% | KeyBanc | $51 → $48 | 維護 | 超重 |
| 08/07/2019 | 65.52% | 雷蒙德·詹姆斯 | $57 → $48 | 維護 | 跑贏大盤 |
| 02/27/2019 | 124.14% | KeyBanc | $67 → $65 | 維護 | 超重 |
| 01/04/2019 | 24.14% | 巴克萊 | $59 → $36 | 評級下調 | 等重→減碼 |
| 12/18/2018 | 131.03% | KeyBanc | $68 → $67 | 維護 | 超重 |
| 10/16/2018 | 137.93% | 巴克萊 | → $69 | 開始承保 | →等重 |
| 10/11/2018 | 113.79% | 摩根士丹利 | $60 → $62 | 維護 | 體重不足 |
| 08/21/2018 | — | 雷蒙德·詹姆斯 | 升級 | 市場表現優於→ | |
| 08/08/2018 | 106.9% | 摩根士丹利 | $58 → $60 | 維護 | 體重不足 |
| 08/08/2018 | 158.62% | KeyBanc | $66 → $75 | 維護 | 超重 |
What is the target price for Avanos Medical (AVNS)?
Avanos Medical(AVNs)的目標價格是多少？
The latest price target for Avanos Medical (NYSE: AVNS) was reported by Morgan Stanley on February 22, 2023. The analyst firm set a price target for $28.00 expecting AVNS to fall to within 12 months (a possible -3.45% downside). 9 analyst firms have reported ratings in the last year.
摩根士丹利於2023年2月22日報道了Avanos Medical(紐約證券交易所代碼：AVNS)的最新目標價。這家分析公司將目標價定為28.00美元，預計AVNs將在12個月內下跌(跌幅可能為-3.45%)。去年有9家分析公司公佈了評級。
What is the most recent analyst rating for Avanos Medical (AVNS)?
分析師對Avanos Medical(AVNs)的最新評級是多少？
The latest analyst rating for Avanos Medical (NYSE: AVNS) was provided by Morgan Stanley, and Avanos Medical maintained their underweight rating.
分析師對Avanos Medical(紐約證券交易所股票代碼：AVNS)的最新評級由摩根士丹利提供，Avanos Medical維持其減持評級。
When is the next analyst rating going to be posted or updated for Avanos Medical (AVNS)?
Avanos Medical(AVNS)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Avanos Medical, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Avanos Medical was filed on February 22, 2023 so you should expect the next rating to be made available sometime around February 22, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括查閲公共財務報表，與Avanos Medical的高管和客户交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Avanos Medical的上一次評級是在2023年2月22日提交的，因此您應該預計下一次評級將在2024年2月22日左右提供。
Is the Analyst Rating Avanos Medical (AVNS) correct?
分析師對Avanos Medical(AVNs)的評級正確嗎？
While ratings are subjective and will change, the latest Avanos Medical (AVNS) rating was a maintained with a price target of $26.00 to $28.00. The current price Avanos Medical (AVNS) is trading at is $29.00, which is out of the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的Avanos Medical(AVNs)評級維持不變，目標價在26.00美元至28.00美元之間。Avanos Medical(AVNs)目前的股價為29.00美元，超出了分析師的預測區間。